Page last updated: 2024-08-24

atorvastatin and fibrinogen

atorvastatin has been researched along with fibrinogen in 65 studies

Research

Studies (65)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	11 (16.92)	18.2507
2000's	39 (60.00)	29.6817
2010's	10 (15.38)	24.3611
2020's	5 (7.69)	2.80

Authors

Authors	Studies
Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS	1
Jagroop, IA; Mikhailidis, DP; Nair, DR; Papadakis, JA; Winder, AF	1
Black, DM	1
de Maat, MP; Haverkate, F; Koopman, J	1
Darko, DA; O'Shea, D	1
Bandinelli, S; Bertolotto, A; Lo Faro, A; Navalesi, R; Penno, G; Ruocco, L	1
Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Miltiadous, GA; Tsimihodimos, VK; Tzallas, CS	1
Alfon, J; Badimon, L; Berrozpe, M; Guasch, JF	1
Rodrigues, M; Sinzinger, H	1
Furberg, CD; Rodrigues, M; Sinzinger, H	1
Chik, G; Christ, ER; Crook, MA; Lumb, PJ; Semra, Y; Wierzbicki, AS	1
Crook, MA; Mikhailidis, DP; Nair, DR; Wierzbicki, AS; Winder, AF	1
Crook, MA; Mikhailidis, DP; Wierzbicki, AS; Winder, AF	1
Donner, MG; Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P	1
Otto, C; Schwandt, P	1
Altman, R; Black, DM; Dujovne, CA; Harris, WS; Overhiser, RW	1
Chik, G; Crook, MA; Lumb, PJ; Wierzbicki, AS	1
Atwal, AS; Davis, M; Hamilton, G; Jagroop, IA; Mikhailidis, DP; Nair, DR; Seifalian, AM	1
Bairaktari, E; Elisaf, MS; Kiortisis, DN; Millionis, H	1
Rosenson, RS; Schaefer, EJ; Tangney, CC	1
Bairaktari, ET; Chatzidimou, KG; Elisaf, MS; Goudevenos, JA; Mikhailidis, DP; Milionis, HJ	1
Bo, M; Fabris, F; Fiandra, U; Mercadante, G; Nicolello, MT; Piliego, T	1
Alt, E; Banyai, M; Banyai, S; Derfler, K; Falger, J; Jansen, M; Koppensteiner, R	1
Barsotti, A; Brunelli, C; Ghigliotti, G; Leslie, S; Olivotti, L; Rossettin, P; Spallarossa, P	1
Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA	1
Derfler, K; Goldammer, A; Heinz, G; Hörl, WH; Jansen, M; Stulnig, T; Wiltschnig, S	1
Asakura, H; Ishino, C; Kanno, M; Matsuda, T; Minami, S; Morishita, E; Nakao, S; Uotani, C	1
Ceska, R; Malik, J; Melenovsky, V; Pisarikova, A; Poledne, R; Simek, J; Skrha, J; Stavek, P; Wichterle, D	1
Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ	1
Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S	1
De Maat, MP; Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; Van De Ree, MA	1
Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R	1
Elly, I; Frieman, A; Gavish, D; Hazanov, N; Leibovitz, E	1
Levy, Y	1
Martus, P; Piorkowski, M; Rauch, U; Schultheiss, HP; Schwimmbeck, PL; Weikert, U	1
Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S	1
Athyros, VG; Elisaf, M; Mikhailidis, DP	1
Aso, Y; Inukai, T; Inukai, Y; Matsumoto, S; Matsutomo, R; Takebayashi, K; Wakabayashi, S	1
Broncel, M; Chojnowska-Jezierska, J; Kostka, B; Marczyk, I; Michalska, M; Sikora, J	1
Abruzzese, G; Avellone, G; Campisi, D; De Simone, R; Di Garbo, V; Licata, G; Raneli, G	1
Bolaman, Z; Kadikoylu, G; Ozgel, N; Yenisey, C	1
Balakhonova, TV; Kukharchuk, VV; Masenko, VP; Pogorelova, OA; Susekov, AV; Tripoten', MI; Zubareva, Mi	1
Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A	1
Ezhov, MV; Kukharchuk, VV; Naumov, VG; Samoĭlenko, EIu; Sergienko, IV; Tvorogova, MG	1
Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U	1
Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E	1
Chin, H; Denu-Ciocca, C; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS	1
Bandios, S; Fotiadis, G; Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Katinios, A; Kougias, P; Liapis, CD; Moumtzouoglou, A; Sailer, N; Vitta, I; Voliotis, K	1
Fehér, G; Horváth, B; Komoly, S; Márton, Z; Szapáry, L; Tóth, K	1
Erem, C; Ersoz, HO; Hacihasanoglu, AB; Karti, SS; Ukinc, K	1
Ak, K; Arsan, S; Eksioglu-Demiralp, E; Iqbal, O; Isbir, S; Tetik, S; Yardimci, T	1
Bachowski, R; Gdula-Dymek, A; Krysiak, R; Okopien, B	1
Choi, D; Chung, N; Jang, Y; Kang, SM; Lee, SH; Park, S	1
Akilli, H; Alihanoglu, Y; Altunkeser, BB; Aribas, A; Ayhan, S; Can, I; Demir, K; Koc, F; Vatankulu, MA	1
Li, W; Liu, K; Ma, A; Shao, L; Wang, J; Wang, Z; Wu, D; Zhang, P; Zhang, Y	1
Brodowski, K; Jaworski, K; Kosior, DA; Krzykwa, A; Opolski, G; Zylińska, E	1
Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W	1
Krysiak, R; Okopień, B; Szkróbka, W	2
Antova, E; Bosevska, G; Bosevski, M; Krstevski, G; Mitevska, I	1
Bednarska-Czerwińska, A; Kowalcze, K; Krysiak, R; Okopień, B	1
Kowalcze, K; Krysiak, R; Okopień, B	3
Coxon, FP; Jalal, MM; Mutch, NJ; Whyte, CS	1

Trials

36 trial(s) available for atorvastatin and fibrinogen

Article	Year
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis, 1999, Volume: 143, Issue:2 Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Treatment Outcome	1999
Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. Journal of cardiovascular risk, 1999, Volume: 6, Issue:2 Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides	1999
Dosing of atorvastatin and increases in fibrinogen level. Atherosclerosis, 1999, Volume: 147, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Reference Values; Treatment Outcome	1999
Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis. Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis, 2000, Volume: 4, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Blood Viscosity; Combined Modality Therapy; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hemorheology; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Immunosorbent Techniques; Lipoproteins, LDL; Male; Middle Aged; Plasma Volume; Pyrroles; Simvastatin	2000
Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia. The American journal of cardiology, 2001, Feb-01, Volume: 87, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin	2001
The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study. Current medical research and opinion, 2000, Volume: 16, Issue:3 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Cholesterol; Exercise Test; Female; Fibrinogen; Heptanoic Acids; Homocysteine; Humans; Male; Middle Aged; Peripheral Vascular Diseases; Pilot Projects; Pyrroles; Statistics, Nonparametric; Tunica Intima; Tunica Media; Ultrasonography	2000
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. European journal of clinical pharmacology, 2000, Volume: 56, Issue:9-10 Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol; Drug Combinations; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides	2000
Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis, 2001, Volume: 155, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin	2001
The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling. Current medical research and opinion, 2001, Volume: 16, Issue:4 Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Drug Monitoring; Fasting; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type V; Lipids; Lipoprotein(a); Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome	2001
Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2001, Volume: 11, Issue:1 Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; Triglycerides	2001
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:4 Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Platelet Aggregation; Pyrroles; Thromboplastin; Thrombosis	2002
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes care, 2002, Volume: 25, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides	2002
Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia. Journal of atherosclerosis and thrombosis, 2002, Volume: 9, Issue:1 Topics: Aged; Anticholesteremic Agents; Antigens; Atorvastatin; Blood Glucose; Factor VII; Female; Fibrinogen; Hemostasis; Heptanoic Acids; Humans; Hyperlipidemias; Isoantigens; Male; Middle Aged; Pyrroles; Risk Factors; Thrombosis; Triglycerides	2002
Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. American heart journal, 2002, Volume: 144, Issue:4 Topics: Apolipoproteins B; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides	2002
Effect of atorvastatin and pravastatin on serum C-reactive protein. American heart journal, 2003, Volume: 145, Issue:2 Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Carotid Arteries; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima	2003
Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia. The American journal of cardiology, 2003, Mar-01, Volume: 91, Issue:5 Topics: Administration, Oral; Adult; Atorvastatin; Biomarkers; Carotid Arteries; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media	2003
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:8 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Factor VIIIa; Female; Fibrinogen; Hemostatics; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Placebos; Pyrroles; Risk Factors; Time Factors; Tissue Plasminogen Activator; von Willebrand Factor	2003
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation. Clinical cardiology, 2004, Volume: 27, Issue:4 Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome	2004
ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thrombosis and haemostasis, 2004, Volume: 92, Issue:3 Topics: Adenosine Diphosphate; Adolescent; Adult; Atorvastatin; Cell Degranulation; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Fibrinogen; Heptanoic Acids; Humans; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrroles; Ticlopidine	2004
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:5 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Deformability; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides	2005
Inflammatory markers and the metabolic syndrome. Atherosclerosis, 2005, Volume: 183, Issue:1 Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome	2005
The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:9 Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus, Type 2; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles	2005
[The comparison of simvastatin and atorvastatin effects on hemostatic parameters in patients with hyperlipidemia type II]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2005, Volume: 18, Issue:106 Topics: Aged; Antithrombin III; Atorvastatin; Factor X; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome	2005
[Randomized FARVATER Study. Part 1. Effect of 10 and 20 mg/day atorvastatin on levels of lipids, C-reactive protein, and fibrinogen in patients with ischemic heart disease and hyperlipidemia]. Kardiologiia, 2006, Volume: 46, Issue:9 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Male; Mass Screening; Middle Aged; Pyrroles	2006
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology : JASN, 2006, Volume: 17, Issue:12 Suppl 3 Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fibrinogen; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Diseases; Lipid Metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Tissue Plasminogen Activator	2006
[Effect of therapy with atorvastatin on parameters of postprandial lipemia and factors of inflammation in patients with ischemic heart disease]. Kardiologiia, 2007, Volume: 47, Issue:2 Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Inflammation; Lipids; Male; Myocardial Ischemia; Postprandial Period; Pyrroles; Treatment Outcome	2007
Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia. Canadian journal of physiology and pharmacology, 2007, Volume: 85, Issue:6 Topics: Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HDL; Coronary Artery Disease; Diabetes Complications; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Antagonists; Male; Middle Aged; Pioglitazone; Pyrroles; Thiazolidinediones; Treatment Outcome	2007
Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. The Annals of pharmacotherapy, 2008, Volume: 42, Issue:1 Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins; Male; Middle Aged; Pyrroles; Renal Dialysis; Serum Albumin	2008
Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2008, Volume: 35, Issue:6 Topics: Aged; Atorvastatin; Biomarkers; Blood Pressure; C-Reactive Protein; Calcinosis; Carotid Stenosis; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Count; Male; Middle Aged; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography	2008
Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. Endocrine, 2009, Volume: 35, Issue:3 Topics: Acute-Phase Proteins; Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Ferritins; Fibrinogen; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors	2009
Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2 Topics: Adenosine Diphosphate; Aged; Aspirin; Atorvastatin; Clopidogrel; Comorbidity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Prospective Studies; Pyrroles; Ticlopidine	2010
Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Diabetes care, 2010, Volume: 33, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cytokines; Factor VII; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Metabolic Syndrome; Plasminogen Activator Inhibitor 1; Prediabetic State; Pyrroles	2010
The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A₂. Clinical cardiology, 2011, Volume: 34, Issue:2 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers, Pharmacological; Chemokine CCL2; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult	2011
Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2011, Volume: 20, Issue:5 Topics: Analysis of Variance; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Chronic Disease; Electric Countershock; Female; Fibrinogen; Health Status Indicators; Heptanoic Acids; Humans; Leukocyte Count; Male; Middle Aged; Pyrroles; Secondary Prevention; Time Factors; Warfarin	2011
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia. Cardiovascular therapeutics, 2015, Volume: 33, Issue:5 Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Dopamine Agonists; Exercise; Female; Fibrinogen; Homocysteine; Humans; Hypercholesterolemia; Hyperprolactinemia; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Middle Aged; Premenopause; Risk Factors; Uric Acid	2015
Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia. Journal of clinical pharmacology, 2019, Volume: 59, Issue:1 Topics: Adult; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperprolactinemia; Lipids; Metabolic Diseases; Middle Aged; Prolactin; Risk Factors	2019

Other Studies

29 other study(ies) available for atorvastatin and fibrinogen

Article	Year
Effect of atorvastatin on plasma fibrinogen. Lancet (London, England), 1998, Feb-21, Volume: 351, Issue:9102 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles	1998
Statins and fibrinogen. Lancet (London, England), 1998, May-09, Volume: 351, Issue:9113 Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Lipoprotein(a); Pyrroles	1998
Statins and fibrinogen. Lancet (London, England), 1998, May-09, Volume: 351, Issue:9113 Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Pyrroles	1998
Statins and fibrinogen. Lancet (London, England), 1998, May-09, Volume: 351, Issue:9113 Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Pyrroles	1998
Statins and fibrinogen. Lancet (London, England), 1998, May-09, Volume: 351, Issue:9113 Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Pyrroles	1998
Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis, 1999, Volume: 145, Issue:2 Topics: Animals; Arteriosclerosis; Atorvastatin; Chemokine CCL2; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; DNA; Down-Regulation; Fibrinogen; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Polymerase Chain Reaction; Pyrroles; Rabbits; Simvastatin; Tunica Intima	1999
Atorvastatin and fibrinogen--a small subgroup shows extreme response. Atherosclerosis, 1999, Volume: 145, Issue:2 Topics: Adult; Aged; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome	1999
Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM : monthly journal of the Association of Physicians, 1999, Volume: 92, Issue:7 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Prospective Studies; Pyrroles; Rhabdomyolysis; Simvastatin; Triglycerides	1999
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia. Atherosclerosis, 2000, Volume: 148, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles	2000
Natural statins and stroke. Circulation, 2000, Jan-25, Volume: 101, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fibrinogen; Heptanoic Acids; Humans; Pyrroles; Risk Factors; Stroke	2000
More on atorvastatin and fibrinogen. Atherosclerosis, 2000, Volume: 151, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Pyrroles	2000
Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. The American journal of cardiology, 2000, Feb-01, Volume: 85, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cholesterol, LDL; Cholesterol, VLDL; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemias; Male; Middle Aged; Pilot Projects; Plasminogen Activator Inhibitor 1; Pyrroles; Single-Blind Method; Treatment Outcome; Triglycerides	2000
Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. Atherosclerosis, 2001, Volume: 159, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Combined Modality Therapy; Erythrocyte Aggregation; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Plasmapheresis; Probability; Prospective Studies; Pyrroles; Rheology; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome	2001
Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia. Metabolism: clinical and experimental, 2002, Volume: 51, Issue:8 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fibrinogen; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides	2002
Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia: additional evidence to support the anti-inflammatory effects of statins. The Israel Medical Association journal : IMAJ, 2004, Volume: 6, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Severity of Illness Index	2004
Beyond cholesterol lowering: effect of statins on markers of cardiovascular disease. The Israel Medical Association journal : IMAJ, 2004, Volume: 6, Issue:8 Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; C-Reactive Protein; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Risk Factors	2004
One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease. International angiology : a journal of the International Union of Angiology, 2006, Volume: 25, Issue:1 Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Platelets; C-Reactive Protein; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Patient Compliance; Pyrroles; Time Factors; Treatment Outcome; Triglycerides	2006
Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia. Journal of the National Medical Association, 2006, Volume: 98, Issue:8 Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Coagulation; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome	2006
E-selectin and TFPI are associated with carotid intima-media thickness in stable IHD patients: the baseline findings of the MIAMI study. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2008, Volume: 18, Issue:4 Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Cholesterol; E-Selectin; Endothelium, Vascular; Female; Fibrinogen; Heptanoic Acids; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Interleukin-8; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Thromboplastin; Triglycerides; Tumor Necrosis Factor-alpha; Tunica Intima; Vascular Cell Adhesion Molecule-1; von Willebrand Factor	2008
[Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients]. Orvosi hetilap, 2008, Jun-15, Volume: 149, Issue:24 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cerebrovascular Disorders; Chronic Disease; Drug Administration Schedule; Endothelium, Vascular; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Hemorheology; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Stroke; von Willebrand Factor	2008
Atorvastatin preconditioning improves the forward blood flow in the no-reflow rats. Fundamental & clinical pharmacology, 2014, Volume: 28, Issue:1 Topics: Animals; Atorvastatin; Echocardiography; Fibrinogen; Fibrosis; Hemodynamics; Heptanoic Acids; Inflammation; Male; Microcirculation; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Pyrroles; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Tumor Necrosis Factor-alpha	2014
[Role of inflammation in etiology of atrial fibrillation--is lone arrhythmia really alone]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2012, Volume: 65, Issue:4 Topics: Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pyrroles; Recurrence	2012
Hyperfibrinogenemia in Peripheral Arterial Disease: Coexistent and Independent Risk Factor (A Report of Two Cases and Review of Literature). Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki), 2018, Dec-01, Volume: 39, Issue:2-3 Topics: Amputation, Surgical; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate; Fibrinogen; Humans; Hypolipidemic Agents; Intermittent Claudication; Ischemia; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Predictive Value of Tests; Risk Factors; Treatment Outcome	2018
The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study. Pharmacological reports : PR, 2019, Volume: 71, Issue:3 Topics: Adrenal Hyperplasia, Congenital; Adult; Androgens; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pilot Projects; Risk Factors; Testosterone; Uric Acid; Vitamin D	2019
The impact of atorvastatin on cardiometabolic risk factors in brothers of women with polycystic ovary syndrome. Pharmacological reports : PR, 2021, Volume: 73, Issue:1 Topics: Adult; Aged; Androgens; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Cardiometabolic Risk Factors; Female; Fibrinogen; Homocysteine; Humans; Hydroxycholecalciferols; Insulin Resistance; Lipids; Male; Middle Aged; Polycystic Ovary Syndrome; Risk Factors; Testosterone; Uric Acid	2021
Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study. Cardiology, 2022, Volume: 147, Issue:5-6 Topics: Androgens; Atorvastatin; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Insulin Resistance; Pilot Projects; Prolactin; Risk Factors; Uric Acid	2022
Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis. Pharmacology, 2023, Volume: 108, Issue:3 Topics: Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cholesterol; Female; Fibrinogen; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors; Thyroiditis, Autoimmune; Uric Acid	2023
Atorvastatin-mediated inhibition of prenylation of Rab27b and Rap1a in platelets attenuates their prothrombotic capacity and modulates clot structure. Platelets, 2023, Volume: 34, Issue:1 Topics: Adenosine Diphosphate; Atorvastatin; Blood Platelets; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prenylation; rab GTP-Binding Proteins; rap1 GTP-Binding Proteins; Thrombosis	2023
The Impact of Atorvastatin on Cardiometabolic Risk Factors in Sisters of Women with Polycystic Ovary Syndrome. Pharmacology, 2023, Volume: 108, Issue:5 Topics: Androgens; Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Female; Fibrinogen; Humans; Insulin Resistance; Polycystic Ovary Syndrome; Risk Factors; Siblings; Testosterone; Uric Acid	2023